Crux Biomedical Overview
Update this profile
Crux Biomedical General Information Description
Developer of a preventive device for pulmonary embolisms. The company provide Crux VCF System, that stops the blood clots from reaching the lungs. It is useful for patients at risk of pulmonary embolism who can't tolerate blood thinners, method of preventing clots.
Want to dig into this profile?
We’ll help you find what you need
Crux Biomedical Valuation & Funding
Raised to Date
6. Later Stage VC (Series D)
5. Later Stage VC (Series C)
4. Later Stage VC (Series B)
3. Later Stage VC
2. Early Stage VC (Series B)
1. Early Stage VC (Series A)
To view Crux Biomedical’s complete valuation and funding history, request access »